Sep 09, 2025
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Aug 21, 2025
Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference
Aug 20, 2025
Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025
Jul 22, 2025
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025
Jul 10, 2025
Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer
Jun 10, 2025
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
May 29, 2025
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
May 06, 2025
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Apr 25, 2025
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer
Apr 22, 2025
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025
Mar 05, 2025
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Feb 25, 2025
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance
Feb 20, 2025
Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference
Dec 16, 2024
Jazz Pharmaceuticals Announces CEO Succession Plan
Dec 06, 2024
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
Dec 05, 2024
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
Dec 04, 2024
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
Dec 03, 2024
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
Nov 20, 2024
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 19, 2024
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference